Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Phytother Res. 2009 Aug;23(8):1066–1074. doi: 10.1002/ptr.2667

Figure 4.

Figure 4

Effect of co-treatment of PAC-1 and Paraplatin on cell viability and cell proliferation and quantification of the uptake of PAC-1 in SKOV-3 in the presence or absence of paraplatin. A: SKOV-3 cells were pretreated with (0–150 μg/mL) for 3 h with PACs, followed by subcytotoxic doses of paraplatin (4.5 μg/mL). Cell viability was measured by MTS assay. B: SKOV-3 cells were pretreated with (0– 125 μg/mL) for 3 h with PACs, followed by subcytotoxic doses of paraplatin (4.5 μg/mL). The BrdU proliferation assay was used to measure inhibition of cell proliferation. Experiments were performed in triplicates; data are expressed as the mean of the triplicate determinations (X ± SD) in % cell proliferation of untreated cell. C: SKOV-3 cells were treated with PAC-1 (200 μg/mL) for 48 h and metabolites quantified by HPLC. D: SKOV-3 cells were pretreated with PAC-1 (200 μg/mL, 3 h) followed by subcytotoxic doses of paraplatin (4.5 μg/mL). Cells were incubated for a total of 48 h and proanthocyanidins were quantified by HPLC.